Actionable news
0
All posts from Actionable news
Actionable news in HZNP: Horizon Pharma, Inc.,

Horizon: Date

The following excerpt is from the company's SEC filing.

/s/ Timothy P. Walbert

Chairman, President and Chief Executive Officer

(Principal Executive Officer)

/s/ Paul W. Hoelscher

Executive Vice President, Chief Financial Officer

(Principal Financial Officer)

INDEX TO EXHIBITS

Exhibit

Number

Description of Document

2.1(1)

Transaction Agreement and Plan of Merger, dated March 18, 2014, by and among Horizon Pharma, Inc., Vidara Therapeutics Holdings LLC, Vidara Therapeutics International Ltd. (now known as Horizon Pharma Public Limited Company), Hamilton Holdings (U SA), Inc. and Hamilton Merger Sub, Inc.*

2.2(2)

First Amendment to Transaction Agreement and Plan of Merger, dated June 12, 2014, by and between Horizon Pharma, Inc. and Vidara Therapeutics Holdings LLC.

2.3(8)

Agreement and Plan of Merger, dated March 29, 2015, by and among Horizon Pharma, Inc., Ghrian Acquisition Inc. and Hyperion Therapeutics, Inc.*

3.1(3)

Memorandum and Articles of Association of Horizon Pharma Public Limited Company.

4.1(4)

Warrant issued by Horizon Pharma, Inc. on December 18, 2007 to Comerica Bank.

4.2(4)

Warrant issued by Horizon Pharma, Inc. on December 18, 2007 to Hercules Technology Growth Capital, Inc.

4.3(4)

Warrant issued by Horizon Pharma, Inc. on November 21, 2008 to Comerica Bank.

4.4(4)

Warrant issued by Horizon Pharma, Inc. on November 21, 2008 to Hercules Technology Growth Capital, Inc.

4.5(5)

Form of Warrant issued by Horizon Pharma, Inc. pursuant to the Securities Purchase Agreement, dated February 28, 2012, by and among Horizon Pharma, Inc. and the Purchasers and Warrant Holders listed therein.

4.6(6)

Form of Warrant issued by Horizon Pharma, Inc. in Public Offering of Units.

4.10(7)

Indenture, dated as of March 13, 2015, by and between Horizon Pharma Investment Limited, Horizon Pharma Public Limited Company and U.S. Bank National Association.

4.11(7)

Form of 2.50% Exchangeable Senior Note due 2022 (included in Exhibit 4.10).

4.12(9)

Indenture, dated as of April 29, 2015, by and between Horizon Pharma Financing Inc. and U.S. Bank National Association.

4.13(9)

Form of 6.625% Senior Note due 2023 (included in Exhibit 4.12).

4.14(10)

First Supplemental Indenture, dated May 7, 2015, by and among Horizon Pharma Public Limited Company, certain subsidiaries of Horizon Pharma Public Limited Company and U.S. Bank National Association.

10.1+(11)

Horizon Pharma, Inc. Deferred Compensation Plan.

10.2+(12)

Horizon...


More